

NALOXONE HYDROCHLORIDE- naloxone hydrochloride spray, metered **Teva Pharmaceuticals, Inc.**

Drug Facts

Active ingredient (in each spray)

Naloxone hydrochloride 4 mg




Purpose

Emergency treatment of opioid overdose

Uses

- to “revive” someone during an overdose from many **prescription pain medications** or **street drugs such as heroin**
- this medicine can save a life

Directions

	<p>Step 1: CHECK if you suspect an overdose:</p> <ul style="list-style-type: none">▪ CHECK for a <u>suspected overdose</u>: the person will not wake up or is very sleepy or not breathing well▪ yell “Wake up!”▪ shake the person gently▪ if the person is not awake, go to Step 2
	<p>Step 2: GIVE 1st dose in the nose</p> <ul style="list-style-type: none">▪ HOLD the nasal spray device with your thumb on the bottom of the plunger▪ INSERT the nozzle into either NOSTRIL▪ PRESS the plunger firmly to give the 1st dose▪ 1 nasal spray device contains 1 dose
	<p>Step 3: CALL</p> <ul style="list-style-type: none">▪ CALL 911 immediately after giving the 1st dose



Step 4: WATCH & GIVE

- **WAIT** 2-3 minutes after the 1st dose to give the medicine time to work
- if the person wakes up: Go to Step 5
- if the person does not wake up:
- **CONTINUE TO GIVE** doses every 2-3 minutes until the person wakes up
- it is safe to keep giving doses



Step 5: STAY

- **STAY** until ambulance arrives: even if the person wakes up
- **GIVE** another dose if the person becomes very sleepy again
- You may need to give all the doses in the pack

Warning

- **When using this product** some people may experience symptoms when they wake up, such as, shaking, sweating, nausea, or feeling angry. This is to be expected.

Other information

- Store below 77°F (25°C).
- do not freeze
- avoid excessive heat above 40°C (104°F)
- protect from light
- the product is packaged in individually-sealed blisters.
Do not use if the blister is open or torn, or if the device appears damaged.

Inactive Ingredients

benzalkonium chloride, edetate disodium, sodium chloride buffered with sodium hydroxide/hydrochloric acid, water

Questions?

1-888-838-2872 between 9 am and 5 pm ET, Monday-Friday.
www.tevausea.com/our-products/tevagenerics

Safe to Use
Even if Opioids are Not Present

*This product is not affiliated with. manufactured by. or produced by

This product is not affiliated with, manufactured by, or produced by
the makers or owners of *NARCAN*®

Manufactured For: Teva Pharmaceuticals USA, Inc.
Parsippany, NJ 07054

Rev. A 1/2024

Package/Label Principal Display Panel - Carton Label

Original Prescription Strength
Easy to Use
Can Save a Life

Compare to the active
ingredient in *NARCAN*®*

NDC 0480-3478-68


Naloxone Hydrochloride
Nasal Spray
4 mg

Emergency Treatment of
Opioid Overdose

Designed to Rapidly Reverse the
Effects of a Life-Threatening
Opioid Emergency

For use in nose only

2 Single-Dose Nasal Spray Devices
0.003 fl oz (0.1 mL) each



NALOXONE HYDROCHLORIDE naloxone hydrochloride spray, metered			
Product Information			
Product Type	HUMAN OTC DRUG	Item Code (Source)	NDC:0480-3478
Route of Administration	NASAL		
Active Ingredient/Active Moiety			
	Ingredient Name	Basis of Strength	Strength
	NALOXONE HYDROCHLORIDE (UNII: F850569PQR) (NALOXONE - UNII:36B82AMQ7N)	NALOXONE HYDROCHLORIDE	4 mg in 0.1 mL
Inactive Ingredients			
	Ingredient Name		Strength
	BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)		
	EDETATE DISODIUM (UNII: 7FLD91C86K)		
	SODIUM CHLORIDE (UNII: 451W47IQ8X)		

HYDROCHLORIC ACID (UNII: QTT17582CB)

WATER (UNII: 059QF0K00R)

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0480-3478-68	2 in 1 CARTON	09/23/2024	
1	NDC:0480-3478-19	1 in 1 BLISTER PACK		
1		0.1 mL in 1 VIAL, SINGLE-DOSE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA209522	09/23/2024	

Labeler - Teva Pharmaceuticals, Inc. (022629579)

Revised: 1/2024

Teva Pharmaceuticals, Inc.